Glembatumumab vedotin
- Generic Name
- Glembatumumab vedotin
- Drug Type
- Biotech
- CAS Number
- 1182215-65-1
- Unique Ingredient Identifier
- 1568H6A58U
- Background
A conjugate of an anti-glycoprotein non-metastatic melanoma protein B mAb and monomethyl auristatin E for the treatment of melanoma and breast cancer.
- Indication
Investigated for use/treatment in melanoma.
Prevalence and Profiles of Treatment-Related Adverse Events in Metastatic Breast Cancer Patients Receiving Antibody-Drug Conjugates
A meta-analysis of 23 clinical trials reveals the prevalence and distinct toxicity profiles of treatment-related adverse events (TRAEs) associated with currently approved antibody-drug conjugates (ADCs) for metastatic breast cancer. Gastrointestinal disorders were highly prevalent across all treatments, with Trastuzumab Deruxtecan and Sacituzumab Govitecan showing higher symptom burdens compared to Trastuzumab Emtansine. The study underscores the importance of understanding these TRAEs to enhance supportive care and develop personalized risk-stratified care pathways.
Glembatumumab Vedotin Fails to Meet Efficacy Endpoint in Recurrent Osteosarcoma Phase II Trial
• Glembatumumab vedotin (GV) was evaluated in a Phase II trial for patients aged 12-50 with relapsed or refractory osteosarcoma.
• The primary endpoint of disease control at 4 months was not met, with only one partial response and two cases of stable disease observed.
• The antibody-drug conjugate was generally well-tolerated, with rash being the most common grade III adverse event, and toxicities similar to previous studies.
• No correlation was found between glycoprotein non-metastatic B (gpNMB) expression and response to glembatumumab vedotin in this patient population.
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath